« Voltar « Back

Biosimilars in Brazil


Sérgio Pinheiro Marçal; Angela Fan Chi Kung; Camila Martino Parise


ImprimirVisualizar em PDF
During the last decades, the development of pharmaceuticals obtained through biological fluids or animal tissues or via biotech procedures has gained momentum and enabled the industry to offer therapeutic alternatives for several complex diseases for which there was no treatment until recently. These pharmaceuticals are costly, though, and widely inaccessible for the general public – which translates into a challenge for every government across the world to find ways to incorporate
those pharmaceuticals into their public healthcare policies. Within this context, biosimilars are seen as an affordable means to expand the access to biopharmaceuticals.

Click download to read the full content
Download do documento
Faça parte do nosso mailing Join our mailing list Receba em primeira mão publicações
e comunicados do escritório
Keep current with our
latest news and events

São PauloRua Hungria, 1100
São Paulo – SP
t. +55 (11) 3247-8400ver mapasee map

Rio de JaneiroRua Humaitá, 275 - 16º andar
Rio de Janeiro – RJ
t. +55 (21) 2506-1600ver mapasee map

BrasíliaSAFS, Qd. 2, Bloco B
Ed. Via Office - 3º andar
Brasília – DF
t. +55 (61) 3312-9400ver mapasee map

Palo Alto228 Hamilton Avenue,
3rd floor
CA 94301 | USAver mapasee map

Tóquio1-6-2 Marunouchi,
Chiyoda-ku, 21st floor
Tokyo | Japan
t. +81 (3) 3216 7191ver mapasee map

Termos de Uso
Política de Privacidade